Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

6322439

Reference Type

Journal Article

Title

Time to treatment discontinuation of second-line fulvestrant monotherapy for HR+/HER2-metastatic breast cancer in the real-world setting

Author(s)

Diamond, JR, JR; Potter, D; Salkeni, M; Silverman, P; Haddad, T; Forget, F; Awada, A; Canon, JL; Luhn, P; O'Hear, C; Ton, TG; Sanglier, T; Hsieh, R; Oliveri, E; Chuo, J; Xiao, Y; Emens, L

Year

2019

Is Peer Reviewed?

Yes

Journal

Cancer Research
ISSN: 0008-5472
EISSN: 1538-7445

Volume

Issue

Page Numbers

P4-13-08-P4-13-08

DOI

10.1158/1538-7445.SABCS18-P4-13-08

Web of Science Id

WOS:000478677001420

URL

https://aacrjournals.org/cancerres/article/79/4_Supplement/P4-13-08/639727/Abstract-P4-13-08-Time-to-treatment
Exit